GTP Bioways, a CDMO dedicated to biotherapeutics manufacturing, and Texcell, a CRO specialized in viral safety, assay development, and GMP banking, are partnering to provide comprehensive services to biopharmaceutical companies.

The alliance brings together know-how in process development and GMP manufacturing of biopharmaceuticals and expertise in viral testing, viral clearance, and bioassays.

GTP and Texcell aim to provide comprehensive support services to biopharmaceutical companies throughout their clinical development.

“Texcell and GTP Bioways share the same business philosophy,” said Alain Sainsot, president of GTP Bioways. “We are both science-driven and customer-centric companies and believe in empathy, integrity, and transparency to build the success of our customer’s programs. It is thus quite natural that our long business relationship turned into a deeper partnership.”

Eric Henriet, president and CEO of Texcell. said: “We are delighted to partner with GTP Bioways. Texcell and GTP Bioways have similar customers and our services are very complementary. Together, we are able to propose to our customers a comprehensive, structured offer from pre-clinical to clinal phases.”

Within the partnership, GTP Bioways provides biomanufacturing capabilities as well as extensive expertise in process development both using mammalian and microbial hosts.

In a statement, GTP Bioways said that it is one of the few CDMOs in Europe able to support biotech companies with services ranging from cell line development to aseptic filling. GTP Bioways’ teams have been involved in the bioproduction industry as a service provider for more than 20 years, supporting the clinical development of hundreds of innovative therapies.

“With the opening of two additional GMP bioproduction units in Toulouse this year, we are strengthening our position as a key CDMO in Europe,” said Sainsot.

“We work closely with our customers to ensure, thanks to our longstanding expertise and technologies, the highest standards of virus safety for their therapeutic products, with confidence and safety. Together, we help protect the health of patients around the world,” said Henriet.